Systems-based management of interconnected chronic conditions—hypertension, diabetes, kidney disease, obesity and cardiovascular risk—addressing fragmented care in both developed and emerging markets worldwide.
Three converging forces make this the moment for connected, systems-based chronic disease management.
Global health has spent a generation winning the fight against infectious disease. That fight is being won: COVID-19, the world's leading cause of death in 2021, had fallen to 20th place by 2023. But chronic disease has quietly become the larger crisis. Non-communicable diseases now account for nearly two-thirds of the world's total health loss from death and disability combined — and the shift from infectious to chronic disease is happening fastest in exactly the low- and middle-income countries least prepared for it.
Source: Global Burden of Disease Study 2023, The Lancet, October 2025 (IHME)
For a quarter century, global health funding has moved in the opposite direction of disease burden. NCDs cause roughly three in four deaths worldwide, yet have received just 1-2% of development assistance for health since 2000 — a gap that hasn't meaningfully closed in 25 years. It's now getting worse, not better: NCD-specific aid fell another 34% between 2020 and 2023, even as total global health funding has collapsed by more than half from its 2021 peak. Governments that underinvested in NCDs for a generation are now confronting the bill, with less money than ever to pay it.
Sources: WHO Global NCD Compact 2020-2030; NCD Alliance; IHME Financing Global Health 2023 & 2025
The promise: the FDA has now authorized more than 1,500 AI-enabled medical devices, and 92% of the world's population is now within reach of a 4G signal capable of running them.
The peril: reach isn't the same as access. Only 68% of the world's population actually uses the internet — a usage gap concentrated overwhelmingly among the poorest, most rural populations, who may have signal but not an affordable device, data plan, or the digital literacy to use it.
Even where tools do reach people, the evidence they help is mixed. A 2025 University of Southampton scoping review screened 1,974 digital health studies and found only 31 addressed multimorbidity self-management — warning that some tools risk increasing the burden on the very patients they're meant to help.
In the US, a 2022 JMIR review found real clinical benefit for Black American patients, now that smartphone ownership is no longer a barrier, but flagged an open question: which design choices actually build trust and sustained use.
The pattern repeats globally: coverage is outrunning both usage and evidence.
Sources: FDA AI-Enabled Medical Device List, March 2026; ITU Facts and Figures, 2024; Smith et al., International Journal of Medical Informatics, 2025 (University of Southampton); JMIR systematic review, 2022
A burden that has flipped and is accelerating. Decades of underfunding now coming due. Technology capable of connecting care — but not yet reaching, or proven for, the people who need it most. Three converging forces — one moment to act.
In Maryland, Soweto, Manila, Montego Bay, Nairobi, and Manchester, patients with interconnected chronic conditions face the same broken system: siloed care that treats diseases separately when they compound each other's risks.
A diabetic patient in Maryland sees an endocrinologist for blood sugar, a cardiologist for blood pressure, and a nephrologist for kidney function—three separate appointments, three disconnected medical records, no one coordinating care. The same fragmentation exists in Soweto, but with added barriers: fewer specialists, longer distances, intermittent connectivity.
The core failure is universal: healthcare systems treat interconnected chronic conditions in silos. One app for diabetes. Another for blood pressure. A third for weight management. Different doctors. Separate records. A 2025 JAMA Network Open review found fewer than 5% of digital health technologies are built for two or more conditions (5 of 148)—so an illustrative patient with five chronic conditions would need up to 13 apps and 7 devices just to cover what clinicians consider essential.
Diabetes treated separately from hypertension, separately from kidney disease—but these conditions are deeply interconnected and compound each other's risks. Universal problem.
Fee-for-service models in developed markets and out-of-pocket payment in emerging markets both reward treatment over prevention. Universal problem.
Healthcare systems wait for crises—ER visits, acute events—rather than preventing complications through continuous monitoring and early intervention. Universal problem.
In developed markets: long wait times, geographic concentration in urban centers. In emerging markets: severe shortage of specialists, patients traveling hours for care. Manifests differently by context.
Developed markets: disconnected apps and EHR systems that don't talk to each other. Emerging markets: limited smartphone access, intermittent connectivity. Manifests differently by context.
One-size-fits-all approaches ignore local dietary patterns, health beliefs, and ability to pay. High-cost solutions exclude underserved populations. Manifests differently by context.
Healthcare costs spiral: Preventable complications drive expensive ER visits, hospitalizations, and specialist interventions that could have been avoided.
Productivity losses: Chronic disease is the leading cause of disability in working-age adults across the US, UK, and Europe.
Preventable deaths: 82% of the 18 million people who die from NCDs before age 70 each year live in low- and middle-income countries, where late diagnosis and fragmented care drive strokes, heart attacks, kidney failure, and amputations (WHO, 2025).
Catastrophic spending: Families pushed into poverty paying out-of-pocket for emergency care that could have been prevented with proactive management.
The outcome is the same everywhere: preventable suffering, avoidable complications, and lives cut short—because healthcare systems fail to manage chronic diseases as the interconnected conditions they are.
Most chronic disease patients don't have just one condition—they have several, and they interact.
When you have diabetes and hypertension together, your risk of kidney disease rises substantially — in one 11-year cohort, roughly 3.6 times higher in men than in those with neither condition (Erfanpoor et al., Int J Endocrinol Metab, 2021). Add obesity, and cardiovascular event risk multiplies further. These aren't separate problems—they're a system that compounds and accelerates.
Yet nearly every existing solution treats them in silos—diabetes app, blood pressure app, weight tracker, separate specialists, fragmented care.
This isn't a new observation. In 2023, the American Heart Association formally defined Cardiovascular-Kidney-Metabolic (CKM) syndrome in a presidential advisory, recognizing that cardiovascular disease, chronic kidney disease, diabetes, and obesity share overlapping metabolic and genetic risk pathways rather than developing in isolation (Ndumele et al., Circulation, 2023).
We don't treat hypertension or diabetes or kidney disease—clinicians do. We support them with a systems-based platform that tracks all conditions together. One patient view. Risk models that account for interactions. AI-assisted clinical decision support that recognizes compounding effects, helping providers manage the interconnected system these conditions actually are.
This is systems-based medicine. This is how chronic disease management should work.
Fragmented chronic disease care isn't just an emerging market problem—it's everywhere. In London, New York, and Sydney, patients with diabetes, hypertension, and kidney disease navigate separate specialists, disconnected apps, and siloed medical records. Same fragmentation. Same poor outcomes. Different income level.
Paying customers across both developed and emerging markets fund platform operations, R&D, and subsidized access for those who cannot afford it.
Underserved populations who cannot afford chronic care receive free or heavily subsidized access, funded by paying customers globally.
✓ Financial sustainability
Not dependent on perpetual grant funding
✓ Health equity
Cross-subsidy ensures underserved populations aren't abandoned
✓ Universal value
Same platform, same quality, everywhere
✓ Scalable impact
Commercial revenue enables reaching millions
Payment capacity, not geography, determines pricing. Outcome improvement is universal.
ChronicDX™ (and ChronicDX Precision) exist to transform chronic disease management wherever healthcare fragments care across interconnected conditions—from underinsured populations in developed markets to underserved communities in emerging markets. Our dual-market model ensures financial sustainability: paying customers globally enable free access for those who need it most, creating health equity through commercial viability rather than perpetual dependence on grants. We build systems that recognize chronic conditions don't exist in silos—they interact, compound, and require integrated care. Our platform combines evidence-based medicine, AI-powered insights, and context-adaptive architecture to support world-class chronic care delivery universally: same platform, same quality, everywhere.
ChronicDX™ transforms chronic disease management through a systems-based platform that addresses interconnected health conditions while ensuring equitable access. Our theory of change demonstrates how targeted interventions create measurable health improvements and sustainable impact. Targets shown are illustrative projections to be validated through rigorous pilot programs.
Inputs combine grant funding, academic partnerships, proven technology, local networks, and target populations to create a foundation for impact. Faculty from Oxford, Yale, Columbia, and Maryland, collaborating in their personal capacities, help shape our clinical protocols, which we will submit for peer review, while context-adaptive architecture ensures accessibility across diverse connectivity environments.
Activities translate resources into action through platform development, clinical protocol validation, pilot programs being designed with partners in 15+ countries spanning Africa, Asia-Pacific, the Caribbean, the Gulf Cooperation Council, the UK, and the United States, community health worker training, and systematic patient enrollment. Each activity is designed for rigorous measurement and continuous improvement.
Outputs are measurable deliverables: 50,000+ active patients by Year 2 across pilot and early-scale markets (building on the initial 35,000-patient Phase 1 cohort), 85% sustained engagement at 12+ months, longitudinal clinical data across five conditions, 200+ physicians using the platform, and 500+ trained community health workers. These outputs demonstrate platform adoption and utilization.
Outcomes represent direct changes resulting from outputs: measurable clinical improvements (HbA1c reduction, blood pressure control, delayed chronic kidney disease progression), 15-25% cost reductions for payers (23% in the illustrative modeling below), prevented complications through early intervention, sustained behavior change in patients, and improved clinical decision-making by providers. These outcomes will be tracked through rigorous pilot programs.
Long-Term Impact emerges from sustained outcomes: improved health equity as underserved populations access the same quality care as affluent communities, a validated scalable model replicable across emerging markets, sustainable health systems operating beyond grant funding through commercial revenue, evidence-based policy change informing systems-based care guidelines, and ultimately, lives extended through better chronic disease management.
Key Assumption: Systems-based care that addresses interconnected chronic conditions will achieve better clinical outcomes and higher patient engagement than siloed single-disease interventions—to be tested in our first pilots against a target of 85% retention at 12 months, compared with roughly 30% typical for chronic disease apps.
ChronicDX™ tracks concrete, measurable outcomes across four dimensions. Targets shown below are illustrative and will be validated through rigorous pilot programs, with results reported quarterly to stakeholders.
All metrics are disaggregated by sex, age, location, and socioeconomic status to ensure equitable outcomes across populations. Data collection follows HIPAA, GDPR, and SOC 2 compliance standards with patient consent and anonymization protocols.
ChronicDX™ addresses common digital health challenges through intentional design choices, proven technical architecture, and strategic partnerships that reduce execution risk.
Unlike traditional apps that treat each condition separately, we connect the dots—helping patients and clinicians see how everything fits together.
Experience how Wellness Connections guides patients through connected chronic care.
Select a step to explore ↓
See all conditions in one connected view
AI flags what needs attention
How conditions interact over time
Evidence-based next steps
Blood Pressure
165/98
↑ Above target for 7 days
HbA1c (Diabetes)
8.2%
↑ Trending up
eGFR (Kidney)
38
↓ Declining
BMI (Weight)
31.4
→ Stable
All metrics in one view. Color-coded by urgency. No switching between apps.
Why managing chronic conditions in silos doesn't work.
Diabetes App
Tracks glucose only. Doesn't know about your BP or kidney function.
BP Tracker App
Records blood pressure. Separate login, separate data.
Weight Loss App
Monitors BMI. Doesn't connect to medication effects.
Medication Reminder
Sends alerts. No clinical context or pattern recognition.
❌ THE PROBLEM
You manage 4 apps, enter data 4 times, and no one connects the dots. When your glucose spikes and your BP rises, no app tells you they're related.
One Platform, All Conditions
Diabetes + Hypertension + Kidney + Weight in one view
AI identifies how conditions interact and compound risk
Medication tracking with clinical context and pattern alerts
Automatic pre-visit summary sent to your provider
✓ THE SOLUTION
One app. One login. One connected view. We map the interactions your single-condition apps miss.
ChronicDX™ offers three integrated platforms tailored to each stakeholder in the chronic disease management ecosystem. Choose your role to explore the product built for you.
Join our waitlist for early access to connected chronic disease management. Launching Q4 2026.
Join Waitlist →Access clinical decision support, patient monitoring dashboards, and seamless EHR integration for better outcomes.
Request Pilot →Support cost reduction, enable better population health outcomes, and access predictive analytics with our integrated platform.
Schedule Demo →Looking for genomic risk stratification? ChronicDX Precision adds a precision-medicine layer on top of the platform above.
Wellness Connections shows you what your doctors see: how your blood pressure, diabetes, kidney health, weight, and heart risk affect each other — and what you can do about it.
Last updated: Today, 9:42 AM
Blood Pressure
138/82
↓ Improving
Blood Glucose
102 mg/dL
↓ Good trend
Weight
78.5 kg
-1.2kg this month
Medications
4 active
92% adherence
🎯 Great progress!
Your weight loss is helping lower both your blood pressure and blood sugar. Keep it up!
📊 How they're connected
Better BP control is protecting your kidneys. Your consistent medication timing is making a difference.
TODAY'S ACTIONS
Morning BP reading logged
Take evening medications (6:00 PM)
Learn how your weight affects your blood pressure, how your blood pressure protects your kidneys, and how your blood sugar impacts everything.
AI identifies patterns across your conditions and explains what they mean — in plain language, not medical jargon.
Track your health even without internet. Data syncs when you're connected. SMS reminders work on any phone.
Available in 20+ languages. Built for your context, not translated from somewhere else.
Be among the first to experience connected chronic disease management. Launching across 15+ countries spanning Africa, Asia-Pacific, the Caribbean, the Gulf Cooperation Council, the UK, and the United States in Q4 2026.
Works offline • SMS support • 20+ languages • Free or subsidized for those who cannot pay
The Clinical Reasoning Platform generates a multi-condition summary with medication adherence, vital signs trends, and AI-flagged priorities — so your 15-minute consultation is spent on decisions, not data gathering.
⚠️ AI Priority Flags:
Cross-Condition Alert: Uncontrolled BP (165/98 × 7 days) accelerating kidney decline (eGFR 42→38 in 6 weeks)
Adherence Issue: Medication adherence dropped from 92% to 60% (missing ACE inhibitor doses)
Data Gap: No home glucose readings in 12 days — last HbA1c 8.2%
⚠️ AI Priority Flags:
Treatment Paradox: LDL 145 mg/dL despite high-dose statin — adherence tracking shows 40% missed doses
Engagement Pattern: Missed 3 appointments in 2 months; no app logins for 18 days
Multi-Condition Risk: HbA1c 9.1% + obesity (BMI 33.2) driving CVD event risk score to 28%
✓ Positive Trends:
Cross-Condition Synergy: Weight loss (-2kg/4wks) improving both BP (138/82) and fasting glucose (112→98 mg/dL)
Excellent Adherence: 94% medication adherence; daily BP/glucose logs; 100% app engagement
Data Quality: Complete vitals history; lifestyle tracking active; care plan goals on track
Be among the first healthcare providers to pilot the platform. Free access, dedicated onboarding, and a direct role in shaping product development.
Population Health Analytics integrates with your existing infrastructure to identify high-risk members, support medication adherence improvement, and demonstrate ROI through claims data integration.
Corporate Health Scheme • Illustrative Analysis
High-Risk Members
892
6.9% of population
Medium-Risk Members
2,341
18.2% of population
Chronic Condition Members
4,218
32.8% of population
App Engagement Rate
76%
3,206 active users
Gender Distribution
54% Female / 46% Male
Avg Age (Chronic)
52.3 years
Age 45+ w/ Chronic
78% (3,290 members)
Multiple Conditions
67% (2,826 members)
Medication Non-Adherence: 1,124 members with <80% adherence driving $4.2M in preventable complications
ER Overutilization: 318 members accounted for 67% of chronic disease ER visits — avg $3,000 per visit
Uncontrolled Comorbidities: 892 high-risk members with 2+ uncontrolled conditions = $12.8M annual cost
Complete Health Records
89% (3,754 members)
Recent Lab Data (<90d)
72% (3,037 members)
Med Adherence Tracked
91% (3,838 members)
Avg Adherence Rate
73% (target: 80%+)
Food Insecurity: 12% (505 members) — 2.3x higher ER use
Transport Barriers: 8% (337 members) — 40% missed appointments
Low Health Literacy: 18% (759 members) — requires culturally adapted content
Illustrative projections for a hypothetical corporate health scheme (12,847 covered lives; 4,218 with chronic conditions). Not actual results; assumptions to be tested in pilots.
Chronic-Condition Claims
-23%
$4.7M net savings
ER Visit Reduction
-28%
915 → 659 visits/year
Medication Adherence
+13 pts
73% → 86% avg
Member Engagement
76%
3,206 active users
57% of total claims costs driven by the 33% of members with chronic conditions
2,826 members with multiple chronic conditions represent the highest per-member cost segment
Projected after 12 months: 28% reduction in ER visits
$4.7M in projected annual net savings
We'll analyze your claims data to identify chronic disease cost drivers and project ROI from our platform.
Enterprise-grade infrastructure meets emerging market constraints.
ChronicDX™ combines four key technology pillars: context-adaptive architecture engineered for universal deployment (full-featured cloud for connected environments, intelligent offline sync for intermittent connectivity), enterprise security and compliance (HIPAA, GDPR, SOC 2), seamless EHR integration (HL7 FHIR), and systems-based AI that identifies root causes across interconnected conditions. Every technical decision prioritizes equity, ensuring underserved populations access the same quality platform as affluent markets.
Cloud-native platform with intelligent offline sync. Mobile app works without internet. SMS gateway for feature phones. Data syncs when connectivity returns.
Engineered for universal deployment: full-featured cloud for connected environments, resilient offline capabilities for intermittent connectivity.
End-to-end encryption (AES-256). SOC 2 Type II certified. Role-based access control. Complete audit logging.
Business Associate Agreements with all vendors. Your health data is protected.
HL7 FHIR R4 compliant API. Works with Epic, Cerner, Athenahealth. Two-way data sync.
No duplicate entry for providers. Seamless integration into existing workflows.
AI identifies root-cause patterns across interconnected conditions that siloed care misses.
Risk stratification accounts for condition interactions, not just individual diagnoses.
Works on feature phones via SMS. Context-adaptive for diverse connectivity environments. 20+ languages. Designed for universal deployment — not a wealthy-market solution retrofitted for underserved populations.
Pricing models that don't exclude underserved populations. World-class care where it's needed most.
Our clinical AI engine is built on explainable, interpretable methods — not black-box predictions.
Our AI engine is built on explainable methods. Every recommendation cites clinical guidelines. Feature importance is displayed for every prediction. Physicians can see exactly why the AI flagged a patient or suggested an intervention.
Trust through transparency. Evidence over black boxes.
The same closed loop. A deeper layer of foresight.
ChronicDX Precision adds genomic risk stratification to the ChronicDX platform — not as a standalone report, but as another input into the same closed-loop system that already connects screening, care, and follow-up. Routed into a care plan that's already tracking your five interconnected conditions, it provides greater foresight. This is grounded in the same clinical logic behind the American Heart Association's 2023 definition of Cardiovascular-Kidney-Metabolic (CKM) syndrome: these conditions don't just co-occur clinically — they share overlapping metabolic and genetic risk pathways, which is exactly what genomic risk stratification is designed to surface earlier.
ChronicDX, Inc. is a global platform company, and Precision will be deployed in select markets as part of that global footprint.
One genomic result, recalculated across your connected care plan
Genetic information carries different weight in different places, and a platform that treats it as culturally neutral will get it wrong. We design for that.
None of this is a footnote. It shapes how we introduce Precision in every market we enter.
Global health, technology, and clinical expertise united by a shared mission
Research partnerships across business, medicine, engineering, cardiovascular science, psychiatry, family medicine, and infectious diseases
Individual faculty members collaborate with ChronicDX™ in their personal professional capacities and do not represent their affiliated institutions
Contact: The Entrepreneurship Centre
Strategic guidance and entrepreneurship support through the Executive MBA program. ChronicDX™ founder is a Director's Award Scholar (Class of 2025). The Strategic Adviser, Asia-Pacific, the Strategic Adviser, UK and South Asia, the Strategic Adviser, Southern Africa, and the Gulf Co-Lead are also Executive MBA candidates (Class of 2025); the Strategic Adviser, Nigeria is a graduate of the School's MSc in Global Healthcare Leadership, which the Strategic Adviser, Pakistan is currently pursuing.
Contact: Professor John Powell
Professor of Digital Health Care, Nuffield Department of Primary Care Health Sciences; Academic Director, MSc in Applied Digital Health; Research focus: digital health technologies, healthcare innovation, patient experience, and health technology assessment. Collaboration through students in the MSc in Applied Digital Health.
Contact: Professor Robin Choudhury, MA, DM, FRCP
Professor of Cardiovascular Medicine, University of Oxford; Consultant Cardiologist, John Radcliffe Hospital; Research Fellow in Biomedical Sciences, Balliol College. Research focus: atherosclerosis, vascular inflammation, cardiovascular molecular imaging, myocardial regeneration, and innate immune programming. Adviser to ChronicDX™ on cardiovascular science.
Contact: Dr. Abhirup Banerjee
Associate Professor, Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford (Wolfson College). Research focuses on cardiovascular science, artificial intelligence, and computational modelling. Technical partnership on medical device development, context-adaptive architecture for diverse deployment environments, and health technology innovation.
Contact: Dr. AZA Stephen Allsop, MD, PhD
Assistant Professor of Psychiatry; Director, AZA Laboratory; Director, Center for Collective Healing at Howard University; National Academy of Medicine Emerging Leaders Scholar. MD from Harvard Medical School, PhD in Neuroscience from MIT. Focus areas: mental health disparities, collective healing, social neuroscience, and integrative wellness approaches for marginalized communities. Co-Director of Clinical Research and Scientific Affairs for ChronicDX™.
Contact: Prof. L. Latéy Bradford, MD, PhD
Family Physician, Core Faculty in Family Medicine, University of Maryland Capital Region Health. PhD in Microbiology and Immunology. Research interests: maternal-child health, health equity, health disparities, community health innovation, and vaginal microbiome dynamics. Chair of Bioethics Committee; New Faculty Scholar, Society of Teachers of Family Medicine. Co-Director of Clinical Research and Scientific Affairs for ChronicDX™.
Contact: Dr. Adjoa Smalls-Mantey, MD, DPhil, DipABLM, FAPA
Strategic Adviser, Mental Health, Lifestyle Medicine, and Research
Assistant Clinical Professor of Psychiatry, Columbia University; Adjunct Assistant Professor of Psychiatry, NYU Grossman School of Medicine; Immediate Past President, New York County Psychiatric Society; Co-Chair, Nutrition Section, American Psychiatric Association Lifestyle Psychiatry Presidential Workgroup. DPhil, University of Oxford (NIH/Oxford Scholar); MD, Columbia University (MD/PhD Program). Focus areas: serious mental illness, emergency and lifestyle psychiatry, nutrition and mental health, and stress management. Role at ChronicDX: guiding the platform's stress and mood module, integrating mental health measures into pilots, and advising on research.
Regional guidance, market access, and operational expertise supporting ChronicDX™ platform deployment across our priority markets.
Contact: Dr. Noel Brathwaite, PhD, MSPH
Director of Research, University of the Southern Caribbean, Port of Spain, Trinidad. Senior Adviser on Sustainability and Fund Raising, Adventist Health System Inter-America (AHSIA). Published researcher on chronic disease in Adventist Caribbean populations. Strategic Adviser to ChronicDX™ with a focus on partnership development across the Inter-American Adventist health network.
Contact: Sultan S. Khodr
Investment Director, King Salman Park. Previously Senior Investment Professional at the Public Investment Fund (PIF), Saudi Arabia's sovereign wealth fund. Oxford Saïd Business School Executive MBA candidate (Class of 2025). Gulf Co-Lead for ChronicDX™, leading investment and capital mobilization, deal structuring, regulatory navigation, and local representation across the Gulf Cooperation Council.
Contact: Dr. Olukayode Fasominu
Physician; Founder, Volte Health. Graduate of Oxford's MSc in Global Healthcare Leadership, Saïd Business School (delivered jointly with the Nuffield Department of Primary Care Health Sciences); Green Templeton College, Oxford. Strategic Adviser to ChronicDX™ for Nigeria and Point-of-Care Digital Technology — anchors the Nigeria track and will contribute to shaping an eventual point-of-care diagnostics/sensing layer for the platform.
Contact: Farai Chikumbu
Co-founder and original developer of epione.net, the digital connectivity platform underpinning Epione Health Villages. BCom (Hons), University of Cape Town. Strategic Projects Head, Oppenheimer Generations; previously Group Digital Transformation & Innovation Product Lead, Mediclinic Group, with earlier roles at Living Goods, Netcare, KPMG South Africa, and SAP. Oxford Saïd Business School Executive MBA candidate (Class of 2025). Strategic Adviser to ChronicDX™.
Contact: Dr. Dawood Anwar
MRCGP, MRCS. Chief Accountable Officer, Salford Primary Care Together, UK NHS. Clinical Operations Lead for ChronicDX™, translating clinical protocols into nurse-led clinic workflows, with a focus spanning the UK NHS, South Asia, and Southern Africa engagements.
Contact: Dr. Sami Malik, MBBS
Dr. Sami Malik is a physician and healthcare management professional with experience in hospital operations, clinical service planning, and digital health transformation. He currently serves as Operations and Technology Management Lead at NovaCare Hospital, Pakistan, where he contributes to clinical strategy, healthcare technology implementation, and operational planning. He holds an MS in Healthcare Management & Innovation from LUMS and is pursuing an MSc in Global Healthcare Leadership at the University of Oxford's Saïd Business School. At ChronicDX™, he advises on market-entry strategy, public-sector partnerships, and pilot opportunities in Pakistan, with a particular focus on scalable digital health solutions that improve access to chronic disease care while reducing costs for patients and health systems.
Contact: Odell Bussue
Founder and Executive Director, Caribbean Health and Education Foundation (CHEF), serving communities across the OECS. Background spanning IT, healthcare administration, and peer-reviewed public health research conducted with Johns Hopkins University. Strategic Adviser to ChronicDX™, focused on chronic disease and digital health tools across the OECS.
ChronicDX™ pursues two parallel paths: commercial deployment in East and Southern Africa, the Gulf Cooperation Council and the United States, and a hybrid model — blending paying and cross-subsidized access — that extends the platform through academic, humanitarian, faith-based and government partnerships in the Caribbean, Asia-Pacific and the United States.
A live, contracted deployment anchored by a physician-owned and led clinic model. Starting from a single-site proof point of several hundred patients and multiple payers and employers, scaling toward capacity for thousands of active patients, a dozen-plus payer schemes, and dozens of employer accounts. Parallel discussions underway with a leading regional health federation on nurse- and community-health-officer-led deployment.
Multiple advanced commercial discussions spanning a community health network already serving thousands of patients across South Africa and Angola, a national private primary-care network with high patient volumes, and a private health-enterprise operator.
Early commercial conversations with regional health systems and with advisers to employer benefits programs, paired with work to build independent US clinical evidence ahead of a commercial launch.
Entry with ChronicDX™ Precision through a global/local collaboration, complemented by deep regional healthcare expertise joining the team in early 2027.
In-principle agreements with a leading international humanitarian relief agency and a major school of nursing, targeting underserved communities.
In-principle agreement with a faith-based regional health network spanning multiple island nations, several with government engagement already underway.
Entry as a follow-up to a major regional initiative covering 60 percent of the world's population — with a policy, academic, and clinical pathway building toward operational collaboration.
All discussions listed, except the Gulf Cooperation Council and the early-stage US commercial track, have reached C-suite level engagement, following successful lower-level reviews.
ChronicDX™ employs a staged blended finance model combining grant funding, impact investment, and commercial revenue to achieve sustainable scale while maintaining mission focus. Patient scale targets and funding amounts shown are illustrative projections based on comparable digital health pilots and will be refined through market validation.
Grants enable what investment cannot: High-risk pilot validation in underserved markets, clinical evidence generation with academic partners, equity-focused features (offline access, feature phone support, local language), and community health worker training infrastructure. Grant funding de-risks the model, creating the validated pathway that attracts commercial capital.
Investment enables what grants cannot: Rapid scale once model is validated, commercial sustainability beyond grant cycles, platform technology R&D at pace required for competitiveness, and geographic expansion across multiple emerging markets. Impact investors bring not just capital but operational expertise, network access, and governance discipline.
Together they create sustainable impact: Grants prove the model works; investment scales what works. Mission and margin align—better health outcomes generate both social impact and financial returns through reduced healthcare costs. This staged approach ensures equity populations aren't abandoned after grant cycles end.
East Africa's Phase 1 cohort builds on the live commercial deployment there. The Gulf Cooperation Council, the UK, the US, and Asia-Pacific sit outside this Phase 1 grant-funded cohort — those tracks are commercial or academic/policy entry points, funded and sequenced separately (see Go to Market Strategy and Traction above).
Following successful Phase 1 validation, ChronicDX™ will raise Series A impact investment to scale across emerging markets. Grant-funded pilots will have de-risked the model with proven clinical outcomes, established unit economics, and validated payer partnerships.
Investment opportunities available to impact investors and mission-aligned funds post-Phase 1 validation. Contact [email protected] for investor materials.
Your health data is protected by enterprise-grade security and regulatory compliance
ChronicDX™ runs on infrastructure provided through our platform partnership with ShareMy.Health, which carries the compliance frameworks and certifications described below.
ChronicDX™'s infrastructure is HIPAA compliant for U.S. health data, treated as Protected Health Information (PHI) with heightened safeguards under applicable Privacy and Security Rules.
For users in the European Economic Area, UK, and Switzerland, ChronicDX™'s infrastructure acts as a data processor under GDPR Article 28, with Standard Contractual Clauses governing cross-border data transfer.
For California users, our infrastructure supports access, deletion, and opt-out rights under the California Consumer Privacy Act (CCPA) and California Privacy Rights Act (CPRA).
For Canadian users and communications, our infrastructure supports compliance with the Personal Information Protection and Electronic Documents Act (PIPEDA) and Canada's Anti-Spam Legislation (CASL).
Multi-layer security architecture with encryption at rest and in transit. SOC 2 Type II certified infrastructure. Regular security audits and penetration testing. Multi-factor authentication and disaster recovery protocols.
You have the right to access, correct, or delete your health data at any time. We never sell your health information to third parties. Data sharing only occurs with your explicit consent or as required by law.
To exercise your privacy rights, request data access, or ask questions about our data practices:
Email: [email protected]
Subject: "Privacy Request" — We respond within 48 hours
Data Governance: Partner organizations (e.g. health systems, employers) and ChronicDX™ act as data controllers; the underlying infrastructure platform acts solely as processor, governed by a written Data Processing Agreement. Subprocessor list available on request. Audit and transaction logs are retained 7 years; primary data is deleted within 30 days of removal, and backups within 3 months.
Data Collection: We collect health information (BP, glucose, weight, medications), account information (name, email, phone), and usage data to provide chronic disease management services. We use this data to generate personalized insights, enable provider communication, and improve our platform. We retain data for as long as you maintain an active account plus 7 years for medical record compliance. Cookies are used for essential functionality and analytics (with your consent).
Based on your experience, or that of family members, we would welcome your feedback via the questionnaires linked below. Completing each will take about 15 minutes, and your responses will be confidential and anonymous.
Questions about ChronicDX™? Partnership inquiries? We'd love to hear from you.